Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and RV1 Using Seven Combined Anti-rotavirus Prevention Programs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is a boy or a girl 2 months ± one week old at the time of the first dose of the vaccine.~* The subject is considered to be healthy based on the clinical history and the physical examination.~* The subject has not received any anti-rotavirus vaccine.~* The parent/tutor fully understands the study's procedures and voluntarily accepts to participate and signs a written informed consent.~* The parent/tutor can meet the study's requirements, such as attending the programmed visits and filling in the journal.~* Written informed consent signed by the parent/tutor before any procedure.~Exclusion Criteria:~* The subject has a background of serious allergic reaction to any of the vaccine's components.~* The subject has a digestive tract malformation or acute/chronic disease.~* The subject has some kind of immunodeficiency including HIV.~* The subject suffers from a haemato-oncological disease.~* The subject has been under treatment with an immunosuppressing medicine including prednisone for two or more weeks.~* The subject has received gamma-globulin or any other blood-derived product or its administration is programmed during the study.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 10 Weeks
- Healthy Volunteers: t

Study Arms:
- ROTA 1 (Type: ACTIVE_COMPARATOR): two doses of monovalent vaccine Rotarix followed by one dose of sterile water
- ROTA 2 (Type: ACTIVE_COMPARATOR): three doses of pentavalent vaccine RotaTeq
- ROTA 3 (Type: ACTIVE_COMPARATOR): one dose of monovalent Rotarix vaccine followed by two doses of pentavalent vaccine Rotateq
- ROTA 4 (Type: ACTIVE_COMPARATOR): one dose of pentavalent RotaTeq vaccine followed by two doses of monovalent vaccine Rotarix
- ROTA 5 (Type: ACTIVE_COMPARATOR): two doses of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix
- ROTA 6 (Type: ACTIVE_COMPARATOR): one dose of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix and a dose of pentavalent vaccine RotaTeq
- ROTA 7 (Type: ACTIVE_COMPARATOR): a dose of monovalent vaccine Rotarix followed by a dose of pentavalent vaccine and a dose of monovalent vaccine Rotarix

Based on this trial design, predict the completion outcome and termination type (if applicable).